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Abstract
Purpose Ventricular access devices (VADs) are commonly
placed in the lateral ventricle but rarely placed in other ven-
tricular compartments. This manuscript describes technical
aspects of VAD placement into the fourth ventricle for the
purpose of treating malignant posterior fossa brain tumors.
Methods As part of a pilot clinical trial to treat recurrent ma-
lignant brain tumors in children, seven patients underwent
posterior fossa craniotomy and placement of a ventricular
catheter under direct vision into the fourth ventricle. The cath-
eter was placed without passing through any brain parenchy-
ma. It was then connected to a VAD placed subcutaneously at
the inferior aspect of the incision. Three of the seven patients
underwent simultaneous subtotal resection of recurrent tumor
located in the fourth ventricle or cerebellum, and one patient
underwent simultaneous tumor biopsy. The VAD was used to
administer chemotherapy (methotrexate) in five of the seven
patients.
Results Six patients had no new neurological deficits after
surgery, and one patient had partial left-sided facial weakness
that was attributed to resection of tumor close to the floor of
the fourth ventricle. No new neurological deficits were caused
by VAD placement or by methotrexate infusions into the
fourth ventricle.
Conclusions AVAD for chemotherapy infusion can be placed
safely into the fourth ventricle without damaging the
brainstem or cerebellum. Attention to anatomical details spe-
cific to the fourth ventricle are important when placing a
fourth ventricle VAD and when using it to administer
chemotherapy.
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Introduction
Infusion of chemotherapy directly into the fourth ventricle of
the brain is a novel means of treatingmalignant posterior fossa
brain tumors that originate in the fourth ventricle. In a recently
published pilot clinical trial [1], seven patients with recurrent,
malignant posterior fossa tumors underwent implantation of a
ventricular access device (VAD) via a posterior fossa craniot-
omy. Five of these seven patients received repeated metho-
trexate infusions into the VAD without any recognized neuro-
logical toxicity, and all three patients with medulloblastoma
had decreased tumor burden after infusions. The promising
results of this trial have led to additional clinical trials testing
infusion of chemotherapy (clinical trials.gov ID NCT
02458339) and expanded autologous natural killer cells (clin-
ical trials.gov ID NCT 02458339) that both recently opened.
VAD placement into the lateral ventricle of the brain is a
common procedure that is familiar to neurosurgeons. Prior to
the recent pilot trial at our institution [1], placement of a VAD
into the fourth ventricle for infusion of chemotherapy had not
been previously reported. The purpose of the current
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manuscript is to detail, for a neurosurgical audience, the tech-
nical nuances required to safely place and use a VAD in the
fourth ventricle.
Methods
Fourth ventricle catheters attached to a VAD were placed in
seven patients enrolled in a pilot clinical trial (clinicaltrials.gov
ID NCT01737671) for infusion of methotrexate into the fourth
ventricle in patients with recurrent, malignant posterior fossa
tumors [1]. Prior to initiation of the study, Investigational New
Drug (IND) exemption was obtained from the FDA (IND
Exemption Number 116804) and institutional review board
approval was obtained from the University of Texas MD
Anderson Cancer Center (Protocol 2012-0823) and
Children’s Memorial Hermann Hospital/University of Texas
Health Science Center at Houston (Protocol HSC-MS-12-
0492). Informed consent was signed by all patients and/or their
legal guardians.
Surgical technique for placement of fourth ventricle
catheter and VAD
Posterior fossa exposure is obtained via a standard midline
suboccipital craniotomy. If resectable tumor is present within
the operative field, maximal safe surgical resection is per-
formed under the operating microscope using standard micro-
surgical techniques. After hemostasis is obtained, a ventricular
catheter is placed into the fourth ventricle and attached to a
VAD placed subcutaneously at the inferior aspect of the inci-
sion as illustrated in Fig. 1.
To safely place the ventricular catheter into the fourth ven-
tricle, the catheter is placed under direct vision using the op-
erating microscope without passing through any brain paren-
chyma (Fig. 2). Great care must be taken to ensure that the
catheter is positioned and secured in a manner that maintains
its position parallel to the long axis of the fourth ventricle to
avoid injury to the brainstem or cerebellum. The catheter is
placed such that all catheter holes are within the fourth ven-
tricle, and the catheter tip is well short of the cerebral aqueduct
to avoid injury to the periaqueductal gray. Once the catheter is
in final position, it is secured with 3-0 prolene sutures in sev-
eral placed to soft tissue and/or dura at the inferior aspect of
the dural opening using the right angle clip provided with the
ventricular catheter (Fig. 3).
After creating a small pocket for the VAD at the inferior
aspect of the incision with a hemostat, the VAD is inserted into
the pocket and secured to the underlying fascia with several 3-
0 prolene sutures (Fig. 3). The catheter is cut to the appropriate
length to allow for a relief loop before attachment to the VAD
(Fig. 4). The relief loop serves to minimize tension on the
catheter with subsequent neck movement postoperatively.
When sizing the catheter appropriately for the relief loop, it
is important to make sure that catheter will be maintained in
this position without any kinking. A 2-0 silk suture is used to
secure the catheter to the VAD.
After the catheter has been secured to the VAD, a
duraplasty is performed either with pericranium, if still present
after previous surgeries, or with an allograft (Fig. 5). When
performing the duraplasty, great care must be taken when
suturing the dural graft around the catheter at the inferior as-
pect of the dural closure. The dural closure must be tight
enough to minimize the possibility of cerebrospinal fluid
(CSF) egress but cannot be so tight that it occludes the cath-
eter. If necessary, as illustrated in Fig. 5, additional pieces of
Fig. 1 Artist’s illustration demonstrating catheter position in the fourth
ventricle parallel to the floor of the fourth ventricle. The catheter is
secured to dura or soft tissue inferior to the dural closure and then has a
relief loop in place to avoid tension on the catheter with neck movement.
It is then attached to a ventricular access device (VAD) that is tunneled
subcutaneously at the inferior aspect of the incision
Fig. 2 Intraoperative image demonstrating catheter placement into the
fourth ventricle. The catheter is placed under the operating microscope
under direct vision without passing through any brain parenchyma
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dural graft, pericranium, or fascia are sutured to the inferior
aspect of the dura to accomplish this goal.
Postoperative imaging prior to using the fourth ventricle
VAD
Postoperatively, an MRI of the brain should be obtained both
to assess baseline tumor burden and to confirm the appropriate
position of the catheter within the fourth ventricle. In general,
the catheter is best visualized on T2-weighted MRI sequences
obtained in at least two planes (Fig. 6). Additionally, prior to
using the VAD to administer chemotherapy, CSF flow from
the fourth ventricular outlets to the cervical, thoracic, and
lumbar spine should be confirmed radiographically. At our
center, this confirmation is obtained by performing CINE
Fig. 3 Intraoperative image demonstrating VAD that has been placed
subcutaneously at the inferior aspect of the incision and secured to
underlying fascia with 3-0 prolene sutures. The VAD will be connected
to the catheter that has been placed and secured to soft tissue and/or dura
at the inferior aspect of the dural opening
Fig. 4 Intraoperative image demonstrating catheter secured to VAD. A
relief loop is placed to minimize tension on the catheter with neck
movement
Fig. 5 Intraoperative image demonstrating dural closure using
duraplasty with allograft. After initial duraplasty, an additional small
piece of allograft is sutured at the inferior aspect of the dural closure to
minimize the possibility of cerebrospinal fluid egress while ensuring that
the catheter is not occluded
Fig. 6 Postoperative T2-weighted MRI scans demonstrating the ventric-
ular catheter in position in the fourth ventricle. The catheter is marked by
an arrow in coronal (a) and axial (b) views
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MRI sequences of the brain and total spine. If CSF flow from
the fourth ventricle to the lumbar spine is not confirmed, then
a nuclear medicine CSF flow study should be obtained.
Performing infusions using the fourth ventricle VAD
Infusions are performed using a 25-gauge butterfly needle
after sterile prep. After accessing the device, CSF is with-
drawn and sent for studies as indicated. Aspiration of fluid
must be performed slowly (no greater than 1 mm per min) to
avoid collapsing the fourth ventricle or aspirating brain tissue
into the catheter holes. Infusions of chemotherapy or other
agents and subsequent flush using preservative-free normal
saline are also performed slowly, at a rate no greater than
1 mm per minute, to avoid any pressure on the adjacent
brainstem or cerebellum.
Results
Seven patients underwent surgery for implantation of a VAD
in the fourth ventricle. Five patients had recurrent medullo-
blastoma, and two patients had recurrent anaplastic
ependymoma. All seven patients had progressive disease de-
spite prior surgery, radiation therapy, and chemotherapy. The
median patient age was 12 years, with a range of 4 to 19 years
old.
All patients underwent successful surgical implantation of
the fourth ventricular catheter and VAD. Simultaneously, three
patients underwent subtotal resection of tumor located in the
fourth ventricle or cerebellum, and one patient underwent si-
multaneous tumor biopsy. The remaining three patients did
not have tumor amenable to simultaneous resection. Six pa-
tients had no new neurological deficits after surgery, and one
patient had new partial left-sided facial weakness postopera-
tively. This patient had undergone simultaneous subtotal re-
section of tumor (anaplastic ependymoma) from the fourth
ventricle. The postoperative seventh nerve palsy was attribut-
ed to resection of tumor adherent to the floor of the fourth
ventricle, and it did not resolve for the duration of follow-
up. Postoperative MRI scans in all seven patients demonstrat-
ed catheter placement within the fourth ventricle without in-
jury to the adjacent brainstem or cerebellum. In all seven pa-
tients, CINEMRI sequences confirmed flow of CSF from the
fourth ventricular outlets to the cervical, thoracic, and lumbar
spinal subarachnoid spaces. Thus, nuclear medicine CSF flow
studies were not performed in any patients.
Two patients never received chemotherapy infusions into
the implantedVADbecause their disease progressed rapidly in
the interval between VAD placement and the planned first
infusions. The remaining five patients underwent, collectively,
a total of 240 infusions of methotrexate into the fourth ventri-
cle as described in the published manuscript describing the
pilot trial [1]. Disease responses are detailed in this publica-
tion. None of the five patients who underwent infusions had
any new neurological deficits related to these infusions, and
none had leukoencephalopathy or other damage to the
brainstem, cerebellum, or cerebral cortex on follow-up MRI
scans after infusions.
Discussion
VAD placement into the frontal horn of the lateral ventricle is
a common procedure familiar to neurosurgeons. VAD place-
ment into the fourth ventricle for the purpose of chemotherapy
infusions, however, has not been reported prior to the recently
published clinical trial from our center [1]. This publication
focused on details of the clinical trial and its results and did not
include the technical aspects of VAD placement. The purpose
of the current manuscript is to describe in detail, for an audi-
ence of neurosurgeons, the technical nuances required to safe-
ly place and utilize a fourth ventricle VAD.
Catheter and VAD placement into the fourth ventricle in
children with posterior fossa tumors may have advantages
over the more traditional means of administering intrathecal
chemotherapy via lumbar puncture or intraventricular chemo-
therapy via lateral ventricle VAD. Lumbar punctures often
require sedation in young children, are technically difficult
in some patients, and are more painful than VAD access. In
prior studies, intrathecal infusions via lumbar puncture
yielded lower and less consistent ventricular drug levels than
intraventricular infusions [2, 3]. Lateral ventricle VAD place-
ment is most commonly a separate surgical procedure per-
formed on a different date than initial posterior fossa craniot-
omy for tumor resection, typically at the time of recurrence.
By placing a fourth ventricle VAD at the time of tumor resec-
tion, a separate surgical procedure and anesthesia administra-
tion can be avoided. Additionally, fourth ventricle catheters
are placed under direct vision using the operating microscope
rather than blindly through cerebral cortex. Catheter place-
ment without passing through any brain parenchyma may po-
tentially decrease the risk of intracerebral hemorrhage and
catheter malposition that can occur with lateral ventricle cath-
eter placement [4–7]. While frameless stereotaxy can mini-
mize catheter malposition with lateral ventricle VAD place-
ment, it cannot guarantee that all catheter holes are within the
ventricle rather than cerebral cortex, especially in patients with
small lateral ventricles. When some catheter holes are within
cerebral cortex, infusion of chemotherapeutic agents directly
into this cortex may contribute to leukoencephalopathy [4,
8–11]. While the sample size of our clinical trial is small, it
is notable that none of the patients who received infusions had
any radiographic or clinical evidence of leukoencephalopathy
after chemotherapy infusions [1]. A larger patient sample will
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be required to determine if fourth ventricle VAD placement
can consistently avoid this complication.
While an additional surgery and some complications
may possibly be avoided by placing a fourth ventricle
VAD, the technical nuances described here are important
tips to avoid complications. If the catheter is not placed
and firmly secured in such a way that it does not touch
the brainstem or cerebellum, injury to these structures is
possible. The catheter must be secured such that it does
not migrate, but neck movement is allowed without ten-
sion on the catheter. When utilizing the catheter, it is
important to aspirate CSF slowly to avoid creating contact
between the catheter and adjacent brainstem or cerebellum.
Similarly, infused agents should be administered slowly to
avoid causing any pressure on the brainstem.
Fourth ventricle VADs may not be the ideal means of ad-
ministering intraventricular chemotherapy to all patients with
malignant tumors originating in the posterior fossa. When
metastatic lesions are present in the lateral and/or third ventri-
cles, higher drug levels may potentially be achieved in these
compartments with a lateral ventricle catheter. The recently
reported pilot trial from our center enrolled only patients with
recurrent disease who had failed standard therapies [1].
However, placement of a VAD into the fourth ventricle for
administration of chemotherapy or novel agents may be most
logical at the time of initial resection when the only remaining
known disease is tumor that is adherent to the floor of the
fourth ventricle. Previous animal studies suggest that drug
administration into the fourth ventricle at that time would
yield high drug levels at the site of residual disease as well
as regional distribution to CSF spaces throughout the neuraxis
[12–14]. Future studies will include placement of VADs into
the fourth ventricle at the time of initial surgical resection for
administration of intraventricular chemotherapy postopera-
tively in selected patients.
Conclusions
Fourth ventricle VADs are not currently utilized at the majority
of centers that treat children with brain tumors. However, on-
going clinical trials may lead to increased interest in direct
delivery of chemotherapy and novel agents into the fourth ven-
tricle after resection of brain tumors that originate in this loca-
tion. Technical nuances described in this manuscript will
facilitate safe placement and utilization of fourth ventri-
cle VADs.
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